Craft
  • Home
  •  / Aligos Therapeutics
Aligos Therapeutics

Aligos Therapeutics

Discovery Projects

2

Q2, 2020

Market Capitalization

$40.5 M

2022-11-21

Aligos Therapeutics Summary

Company summary

Overview
Aligos Therapeutics is a company that develops curative therapies for hepatologic diseases and viral infections. It discovers and develops compounds that interact with disease-causing molecules such as viral nucleic acids and their encoded proteins, as well as oncogenes and their resultant proteins.
Type
Public
Status
Active
Founded
2018
HQ
South San Francisco, CA, US | view all locations
Website
https://www.aligos.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Julian Symons

    Julian Symons, Executive Vice President, Chief Scientific Officer

  • Sushmita M. Chanda

    Sushmita M. Chanda, Executive Vice President, Translational Safety Sciences

  • John Fry

    John Fry, Executive Vice President Clinical Development

  • Matthew W. McClure

    Matthew W. McClure, Executive Vice President Chief Medical Officer

Operating MetricsView all

Discovery Projects

2

Q2, 2020

Pre-Clinical Phase Products

4

Q2, 2020

Phase I Trials Products

1

Q2, 2020

LocationsView all

2 locations detected

  • South San Francisco, CA HQ

    United States

    1 Corporate Dr 2nd floor

  • Leuven, Vlaanderen

    Belgium

    Gaston Geenslaan 1/building 3

Aligos Therapeutics Financials

Summary financials

Net income (Q2, 2022)
($19.9M)
EBIT (Q2, 2022)
($20.4M)

Footer menu